1. Introduction {#sec1-cancers-12-00874}
===============

Hepatocellular carcinoma (HCC) is the fifth most commonly occurring type of cancer and the leading cause of mortality in cirrhotic patients \[[@B1-cancers-12-00874]\]. Despite the recent improvement in diagnosis and screening programs in cirrhotics, a great number of patients are still diagnosed in the advanced stage, thus being unsuitable to curative treatments, such as surgery, orthotopic liver transplantation, or radiofrequency ablation \[[@B2-cancers-12-00874],[@B3-cancers-12-00874],[@B4-cancers-12-00874]\]. Therefore, the identification of prognostic factors for HCC occurrence is of paramount importance in order to decrease the burden of this disease, in particular in high-risk populations, such as cirrhotic or chronic hepatitis B virus (HBV) patients.

Three-hydroxy-3-methyl-glutaryl-coenzyme A (HMG co-A) reductase inhibitors (statins) are effective and commonly used worldwide as a treatment for dyslipidemia, and increasing evidence shows that statins also have anti-inflammatory and anti-oncogenic effects \[[@B5-cancers-12-00874],[@B6-cancers-12-00874]\].

A previous meta-analysis, based on 10 studies, shed light on the beneficial role of statins in preventing HCC occurrence \[[@B7-cancers-12-00874]\]; however, the relatively low number of studies included did not allow subgroup analyses based on the specific agent administered (type of statin) or to correlate the anticancer effect with the dose.

In the last years, several cohort and case--control studies have been published in the field, hence the need to update the previous data in order to better define the eventual chemopreventive role of statins in hepato-oncology.

The aim of this meta-analysis was to provide a pooled estimate of the impact of statin use on HCC occurrence. Primary endpoint was defined as the time-dependent correlation between statin use and HCC incidence (in terms of both crude and adjusted hazard ratio \[HR\] for several baseline variables). Secondary outcome was the correlation between the overall incidence of HCC and statin administration expressed in terms of the odds ratio (OR), again both crude and adjusted.

2. Results {#sec2-cancers-12-00874}
==========

2.1. Characteristics of Included Studies {#sec2dot1-cancers-12-00874}
----------------------------------------

As shown in [Figure 1](#cancers-12-00874-f001){ref-type="fig"}, out of 5562 studies initially identified, after preliminary exclusion of manuscripts not fulfilling inclusion criteria, 95 potentially relevant articles were examined. Among these studies, 23 overlap series and 47 studies not reporting OR or HR (or data useful for their calculation) were further excluded.

Finally, 25 studies reporting 21,576 cases of HCC in 1,925,964 patients were included in the meta-analysis \[[@B8-cancers-12-00874],[@B9-cancers-12-00874],[@B10-cancers-12-00874],[@B11-cancers-12-00874],[@B12-cancers-12-00874],[@B13-cancers-12-00874],[@B14-cancers-12-00874],[@B15-cancers-12-00874],[@B16-cancers-12-00874],[@B17-cancers-12-00874],[@B18-cancers-12-00874],[@B19-cancers-12-00874],[@B20-cancers-12-00874],[@B21-cancers-12-00874],[@B22-cancers-12-00874],[@B23-cancers-12-00874],[@B24-cancers-12-00874],[@B25-cancers-12-00874],[@B26-cancers-12-00874],[@B27-cancers-12-00874],[@B28-cancers-12-00874],[@B29-cancers-12-00874],[@B30-cancers-12-00874],[@B31-cancers-12-00874],[@B32-cancers-12-00874]\].

The main characteristics of the included studies are reported in [Table 1](#cancers-12-00874-t001){ref-type="table"}.

The recruitment period ranged from 1988 to 2018. Nine studies \[[@B8-cancers-12-00874],[@B10-cancers-12-00874],[@B12-cancers-12-00874],[@B13-cancers-12-00874],[@B14-cancers-12-00874],[@B18-cancers-12-00874],[@B20-cancers-12-00874],[@B22-cancers-12-00874]\] were retrospective case--control, twelve were cohort studies \[[@B9-cancers-12-00874],[@B11-cancers-12-00874],[@B15-cancers-12-00874],[@B16-cancers-12-00874],[@B17-cancers-12-00874],[@B19-cancers-12-00874],[@B23-cancers-12-00874],[@B24-cancers-12-00874],[@B26-cancers-12-00874],[@B27-cancers-12-00874],[@B29-cancers-12-00874],[@B30-cancers-12-00874]\], one study was a randomized controlled trial (RCT) \[[@B28-cancers-12-00874]\], and two studies that were included as RCTs represented individual patient data analysis of patients enrolled in prospective controlled trials of cholesterol in heart disease \[[@B31-cancers-12-00874],[@B32-cancers-12-00874]\]. The study by Tran et al. \[[@B25-cancers-12-00874]\] included two different stages, a nested case--control and a prospective cohort drawn from two different populations, hence they were analyzed separately.

Five studies \[[@B10-cancers-12-00874],[@B11-cancers-12-00874],[@B20-cancers-12-00874],[@B26-cancers-12-00874],[@B27-cancers-12-00874]\] were conducted in the same population (Taiwan National Health Insurance and Research Database) but they reported different outcomes or data from different subgroups, therefore were considered separately in different analyses. Nine studies were conducted in Asia \[[@B10-cancers-12-00874],[@B11-cancers-12-00874],[@B15-cancers-12-00874],[@B16-cancers-12-00874],[@B18-cancers-12-00874],[@B20-cancers-12-00874],[@B26-cancers-12-00874],[@B27-cancers-12-00874],[@B28-cancers-12-00874]\], and the remaining studies were conducted in western countries. The two aforementioned individual patient data analyses concerned multicenter RCTs \[[@B31-cancers-12-00874],[@B32-cancers-12-00874]\].

Baseline clinical and demographical characteristics were well balanced between statin users and the control group. Variables adjusted for were mainly age, sex, and etiology of the underlying liver disease; other comorbidities; and the use of other medications.

Quality was deemed mainly high with five observational studies assessed as low-quality articles \[[@B13-cancers-12-00874],[@B16-cancers-12-00874],[@B19-cancers-12-00874],[@B23-cancers-12-00874],[@B29-cancers-12-00874]\].

Details on methodological characteristics and quality of included articles are shown in [Table S1](#app1-cancers-12-00874){ref-type="app"}.

2.2. Risk of HCC {#sec2dot2-cancers-12-00874}
----------------

As reported in [Figure 2](#cancers-12-00874-f002){ref-type="fig"}A, overall crude OR for HCC incidence was 0.59 (95% CI: 0.47--0.74), thus highlighting a significant protective role of statins against HCC occurrence (*p* \< 0.001). Of note, high evidence of heterogeneity was observed (I^2^ = 92%).

Adjusted analysis, considering the aforementioned baseline confounders, confirmed the anti-oncogenic effect of statins, with a reported adjusted OR (aOR) as high as 0.74 (95% CI: 0.70--0.78). Heterogeneity slightly decreased to 79% in adjusted analysis ([Figure 2](#cancers-12-00874-f002){ref-type="fig"}B).

Crude HR was reported only in two studies \[[@B17-cancers-12-00874],[@B29-cancers-12-00874]\], confirming the above reported results in favor of statin use (HR: 0.42, 95% CI: 0.39--0.45), with moderate evidence of heterogeneity (I^2^=37%; [Figure 3](#cancers-12-00874-f003){ref-type="fig"}A). As described in [Figure 3](#cancers-12-00874-f003){ref-type="fig"}B, when adjusting for several clinical and demographical parameters, the HR slightly increased but remained under the significance threshold (adjusted \[aHR\]: 0.73, 95% CI: 0.69--0.76; I^2^=96%).

There was no evidence of publication bias (data not shown).

2.3. Subgroup Analysis {#sec2dot3-cancers-12-00874}
----------------------

The aHR for HCC occurrence was confirmed as significantly in favor of statins in HBV patients (0.46, 95% CI: 0.36--0.60; I^2^ = 0%) while only a non-significant benefit was observed in HCV patients, although this result should be interpreted with caution due to the low number of studies and the high heterogeneity ([Table 2](#cancers-12-00874-t002){ref-type="table"}).

Statins were proved to be effective in both diabetic and non-diabetic patients, while the magnitude of the chemopreventive effect was found to be linearly correlated to the dose, with an aHR of 0.51 (95% CI: 0.30--0.88) and 0.27 (95% CI: 0.11--0.67) in patients administered a cumulative defined daily dose (cDDD) below or beyond 365, respectively ([Table 2](#cancers-12-00874-t002){ref-type="table"}).

Lipophilic statins (atorvastatin, lovastatin, and simvastatin) were associated with significantly reduced HCC (aHR: 0.49, 95% CI: 0.39--0.62, I^2^ = 19%) incidence while an association between hydrophilic statins (pravastatin, rosuvastatin, and fluvastatin) and reduced risk for HCC was not found (aHR: 0.73, 95% CI: 0 0.40--1.34) ([Table 2](#cancers-12-00874-t002){ref-type="table"}).

Analysis conducted according to single agents found a significant beneficial effect only with atorvastatin (aHR: 0.43, 95% CI: 0.28--0.65, I^2^=17%), although further studies are warranted to provide definitive results in this regard.

2.4. Sensitivity Analysis {#sec2dot4-cancers-12-00874}
-------------------------

The results of several sensitivity analyses are reported in [Table 3](#cancers-12-00874-t003){ref-type="table"}.

The findings of main analysis were confirmed in sensitivity analysis performed according to study quality (high versus low), design (RCT versus observational), and location (Asia versus western).

The only exception was the sub-analysis restricted to RCTs, where an OR around 1 was observed; of note, two out of three studies included as RCTs represented individual patient data analysis of patients enrolled in prospective controlled trials of cholesterol in heart disease (hence, non-cirrhotic) \[[@B31-cancers-12-00874],[@B32-cancers-12-00874]\] where the incidence of HCC was very low.

Heterogeneity in the sensitivity analysis was mainly moderate.

3. Discussion {#sec3-cancers-12-00874}
=============

HCC is one of the most common cancer types and the leading cause of tumor-related deaths in cirrhotic patients \[[@B1-cancers-12-00874]\].

Statins have been shown to consistently reduce liver fibrosis progression, mainly due to their immunomodulatory effects \[[@B33-cancers-12-00874]\], to mitigate portal hypertension, and to upregulate transcription factors that exert vasoprotective effects in the liver and inhibit stellate cells, thus potentially further decreasing fibrosis \[[@B34-cancers-12-00874]\]. On the other hand, the enthusiasm towards statins has been tempered by fears about their safety profile in cirrhotic patients because of the risk of dose-dependent hepatic injury \[[@B35-cancers-12-00874]\].

A previous meta-analysis found a 37% decreased risk of HCC occurrence in statin users \[[@B7-cancers-12-00874]\] but a specific analysis aiming to identify higher-risk settings was unfeasible due to the low number of included studies.

Through a meta-analysis of 25 studies, we made several key observations. First, we found a 26% decreased incidence of HCC in patients treated with statins, after adjustment for several variables. When considering a time-dependent outcome, such as HR, not influenced by the imbalance in follow-up length between the studies, we confirmed a 27% decreased incidence of HCC when adjusting for several clinical and demographical parameters.

Second, this effect was more pronounced and consistent in HBV patients (56% decrease in HCC incidence) and it was found to be linearly correlated to the dose, with a 73% decreased HCC risk in patients administered a cDDD beyond 365.

Third, as already observed in previous individual studies \[[@B24-cancers-12-00874],[@B27-cancers-12-00874]\], lipophilic statins (atorvastatin, lovastatin, and simvastatin) were associated with significantly reduced HCC (51% compared to 27% in hydrophilic statin users). Among several agents tested, the more pronounced chemopreventive effect was observed with atorvastatin (57% reduction in HCC occurrence), although further studies are warranted to provide definitive results in this regard.

This preventive effect of statins is likely to be independent of its lipid-lowering effects, because lipid-lowering agents other than statins were not associated with reduction in the risk of HCC in previous reports \[[@B26-cancers-12-00874],[@B30-cancers-12-00874]\].

The chemopreventive effect of statins in Asian populations, mainly affected by HBV hepatitis/cirrhosis, is well recognized and it was strongly confirmed in our analysis. In fact, HBV genome integration determines several DNA modifications and microdeletions that can target cancer-relevant genes, potentially providing hepatocytes with a growth advantage \[[@B36-cancers-12-00874]\]. Statins, by inhibiting the mevalonate pathway, can prevent potential detrimental effects of these growth signaling proteins \[[@B37-cancers-12-00874]\]. Statins also exert pro-apoptotic effects by activating several caspases and decreasing Bcl-2 \[[@B37-cancers-12-00874]\]. Moreover, statins inhibit the activation of the proteasome pathway, limiting the breakdown of some molecules with growth-inhibitory effects, such as p21 and p27 \[[@B37-cancers-12-00874]\].

On the other hand, the anti-oncogenic effect of statins in HCV patients is less evident, probably due to modification of metabolic syndrome, insulin-mediated cell proliferation, and obesity-associated inflammation \[[@B33-cancers-12-00874],[@B38-cancers-12-00874]\]. A clear relationship between statin use and HCC incidence in HCV patients was not found in our meta-analysis, but this result might be due to the low number of studies specifically evaluating this subset of patients.

One of the novel findings in our study is the clear dose-dependent effect of statins in decreasing HCC occurrence, with 365 cDDDs as the cut-off to observe the highest preventive effects, as already reported in previous individual studies \[[@B28-cancers-12-00874]\]. Several biological properties of statins, such as anti-angiogenetic or anti-fibrotic effects, were found to be strictly associated to the dose used in in vivo studies \[[@B39-cancers-12-00874],[@B40-cancers-12-00874]\].

The greater chemoprotective effect of lipophobic statins, clearly outlined by our analysis, is likely due to greater lipid solubility and membrane permeability which enhance their pharmacological effects \[[@B41-cancers-12-00874]\]. Further studies are needed to confirm these findings.

Of note, sensitivity analysis restricted to RCTs did not show a significant preventive benefit with statins although the result should be interpreted with caution due to the low number of RCTs included. It is evident that the limited number of RCTs was insufficient to detect a significant effect of statins, in particular considering that these RCTs were conducted in non-cirrhotic patients, hence with a very low HCC incidence.

There are some limitations to our study. First, the limited number of studies in many subgroups does not allow a strong comparison between statins users and non-users in several subsets of patients, in particular concerning single pharmacological agents or based on the use of specific antiviral treatments. Second, several comparisons were weakened by the high heterogeneity. We performed different sensitivity analyses that confirmed the main results and, noteworthy, the heterogeneity decreased when several subgroups were considered separately. To take into account the potential baseline confounders, we considered in our primary analysis the aHR. However, even if the heterogeneity decreased, it remained significant, probably none of the studies adjusted for the same confounders. Other eventual source of heterogeneity could be represented by the different populations enrolled in the included studies, with different risk of HCC occurrence and probably uneven screening campaigns in the different geographic areas. Finally, most of the included studies were retrospective series, hence prone to selection bias.

In conclusion, despite these weaknesses, our meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins.

Further studies are warranted to confirm these results and to identify the exact setting where this anti-oncogenic effect could be enhanced.

4. Methods {#sec4-cancers-12-00874}
==========

4.1. Inclusion and Exclusion Criteria {#sec4dot1-cancers-12-00874}
-------------------------------------

Only studies meeting the following criteria were included: (1) RCTs or observational studies recruiting \>10 patients with clear exposure to statin therapy; (2) studies published in English; (3) articles reporting HCC occurrence; and (4) studies reporting OR, HR, or data useful for their calculation. Case reports, non-clinical studies, review articles, and animal models were excluded.

4.2. Search Strategy {#sec4dot2-cancers-12-00874}
--------------------

[Figure 1](#cancers-12-00874-f001){ref-type="fig"} reports the search strategy followed in the meta-analysis.

Bibliographic research was conducted on PubMed, EMBASE, Cochrane Library, and Google Scholar including all studies fulfilling inclusion criteria published until December 2019.

The search was conducted by two study investigators (AF and MAA) independently and keywords used were "HMG-CoA reductase inhibitor(s)," "statin(s)," "atorvastatin," "fluvastatin," "lovastatin," "pravastatin," "rosuvastatin," or "simvastatin" combined with "liver cancer" or "neoplasm(s)."

Relevant reviews and meta-analyses on the use of statins and HCC occurrence were examined for potential suitable studies. Authors of included studies were contacted to obtain full text or further information when needed.

The quality of included studies was assessed by two authors independently (AF and MAA) according to the Cochrane Collaboration's tool for assessing the risk of bias \[[@B42-cancers-12-00874]\] for RCTs and the Newcastle--Ottawa scale \[[@B43-cancers-12-00874]\] for non-randomized studies. Disagreements were solved by discussion and following a third opinion (RS).

4.3. Statistical Analysis {#sec4dot3-cancers-12-00874}
-------------------------

Primary endpoint of the current meta-analysis was the comparison of HCC occurrence between statin users and non-statin users. Data of HCC occurrence were compared through a random-effects model based on the DerSimonian and Laird test, and summary estimates were expressed in terms of both HR and OR along with their relevant 95% CIs.

To partially obviate the bias due to the different follow-up length among the studies and, within each study, between the two treatment arms and to consider not only the number of events but also their timing and the follow-up of censored patients, HRs were considered in the analysis when reported in the included studies.

Two separate analyses were conducted for crude and adjusted summary estimates (both OR and HR) and aHR was considered the primary endpoint in the meta-analysis.

Chi-square and I² tests were used for across studies comparison of the percentage of variability attributable to heterogeneity beyond chance. *p* \< 0.10 for chi-square test and I² \<20% were interpreted as low-level heterogeneity.

Probability of publication bias was assessed using funnel plots and with Begg and Mazumdar's test.

Sensitivity analysis was conducted according to the quality of included studies (high versus low), location of the studies (Asia versus western), and study design (RCT versus observational).

A subgroup analysis based on several statin molecule and class (lipophilic versus hydrophilic), etiology of liver disease, presence of diabetes, and cumulative defined daily dose (cDDD: ≤365 versus \>365) was performed.

All statistical analyses were conducted using RevMan 5.3 software (the Cochrane Collaboration, Oxford, UK). For all calculations a two-tailed p-value of \<0.05 was considered statistically significant.

5. Conclusions {#sec5-cancers-12-00874}
==============

Our meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins. Further studies are warranted to confirm these results and to identify the exact setting where this anti-oncogenic effect could be enhanced.
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cancers-12-00874-t001_Table 1

###### 

Characteristics of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, Year                                         Design, Period                                                                                             Country                                                                                                                    Sample Size                                                                                                  Age                                      Men, *n* (%)                         Liver Disease Etiology (HBV/HCV/alcohol/NASH)                  Follow-Up Period                       Statin Use Period or Dose                                                   Outcome Measure   Variables Adjusted for
  --------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------- ------------------------------------ -------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------
  Björkhem-Bergman, 2014 \[[@B8-cancers-12-00874]\]   Case--control, July 2006 to December 2010                                                                  Swedish Cancer Register                                                                                                    HCC group: 3994 patients (of which 687 statin users)\                                                        Mean age NR                              52%                                  NR                                                             4 years                                At least 9 months                                                           OR, aOR           Age, sex, diabetes, education, other drugs, liver disease etiology
                                                                                                                                                                                                                                                                                            Control (non-HCC), 19970 patients (of which 3598 statin users)                                                                                                                                                                                                                                                                                                                                 

  ERCHIVES: Butt, 2015 \[[@B9-cancers-12-00874]\]     Retrospective cohort, between 2002 and 2013                                                                USA                                                                                                                        Statin users: 3347\                                                                                          Statin users: 53 (Non-statin users: 52   Statin Users: 3226 (96.4%)\          HCV all patients                                               10 years                               Mean (IQR) months: Statin users: 31.7 (13.3--58.5)                          HR, aHR           Baseline FIB-4
                                                                                                                                                                                                                                                                                            Non-users: 3901                                                                                                                                       Non-users: 3702 (94.9%)                                                                                                                                                                                                                  

  Chang, 2017 \[[@B10-cancers-12-00874]\]             Nested case--control (propensity score matching retrospective study), 1 January 2000 to 31 December 2013   Taiwan NHIRD database (Taiwan's National Health Insurance)                                                                 Statin users: 675\                                                                                           56.5±11.2\                               Statin users: 492 (73%)\             313 (46%)/146 (22%)/219 (32%), 292 (43%)/152 (23%)/231 (34%)   Statin users: 5.5 years (3.5)\         Patient with cDDDs \>28 were considered as statin user                      aHR               Age, sex, diabetes, comorbidities, other drugs, liver disease etiology
                                                                                                                                                                                                                                                                                            Non-users: 675                                                                                               57.5 (14.1)                              Non-users: 476 (71%)                                                                                Non-users: 5.4 years (3.6)                                                                                                           

  Chen, 2014 \[[@B11-cancers-12-00874]\]              Propensity score matching retrospective cohort, 1 January 2000 to 31 December 2008                         Taiwan's National Health Insurance (NHI) Research Database (NHIRD)                                                         Statin users*:* 8861\                                                                                        Mean NR                                  Statin users*:* 4869 (54.95%)\       All patients HBV                                               9 years                                Patients who used statins for \<28 cDDDs were defined as statin non-users   aHR               Age, sex, comorbidities, other drugs
                                                                                                                                                                                                                                                                                            Statin + metformin: 5152\                                                                                                                             Statin + metformin: 2650 (51.44%)\                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                            Non-users: 53037                                                                                                                                      Non-users: 30726 (57.93%)                                                                                                                                                                                                                

  El-Serag, 2009 \[[@B12-cancers-12-00874]\]          Nested case--control, 1997--2002                                                                           Department of Veterans Affairs (VA) National Databases, USA                                                                HCC group: 1303 patients of which 447 statin users\                                                          HCC group: 72 years\                     HCC group: 1286 (99%)\               HCC group: 25 (1.9%)/192 (14.7%)/215 (16.5%)/\                 5 years                                Statin use defined as \>3 prescriptions                                     OR, aOR           Etiology of liver disease, cirrhosis, race, other drugs
                                                                                                                                                                                                                                                                                            Control (non-HCC): 5212 patients of which 2766 non-users                                                     Control (non-HCC): 72 years              Control (non-HCC): 5144(99%)         Control (non-HCC): 11 (0.2%)/93 (1.8%)/60 (1.2%)                                                                                                                                                    

  Friedman, 2016 \[[@B13-cancers-12-00874]\]          Case--control, 1 January 1996 to 30 June 2014                                                              Kaiser Permanente Northern California, USA                                                                                 HCC group: 2877 patients of which 701 statin users\                                                          NR                                       NR                                   NR                                                             18 years                               NR                                                                          aOR               Liver disease etiology, comorbidities, other drugs, BMI
                                                                                                                                                                                                                                                                                            Control group (non-HCC): 142850 patients of which 44953 statin users                                                                                                                                                                                                                                                                                                                           

  German, 2019 \[[@B14-cancers-12-00874]\]            Case--control, 2002--2016                                                                                  Wisconsin (USA)                                                                                                            HCC group: 34 patients of which 6 statin users\                                                              HCC group: 68.9±11.4\                    HCC group: 22\                       NAFLD all patients                                             14 years                               NR                                                                          OR, aOR           Age, sex, other drugs
                                                                                                                                                                                                                                                                                            Control group (non-HCC): 68 patients of which 34 statin users                                                Control group (non-HCC): 69.4±7.5        Control group (non-HCC): 44                                                                                                                                                                                                              

  Goh, 2019 \[[@B15-cancers-12-00874]\]               Retrospective cohort, January 2008 to December 2012                                                        Single institution in Seoul, Republic of Korea                                                                             Statin users: 713\                                                                                           Statin users: 50 (44--56)\               Statin users: 482 (67.6%)\           HBV (all patients)                                             7.2 years (0.5--9.7)                   cDDD \>28 was considered as statin use                                      HR, aHR           Age, sex, liver cirrhosis, comorbidities, viral level, other drugs, liver function tests
                                                                                                                                                                                                                                                                                            Non-users: 7000                                                                                              Non-users: 47 (39--54)                   Non-users: 4624 (66.1%)                                                                                                                                                                                                                  

  Hsiang, 2015 \[[@B16-cancers-12-00874]\]            Propensity score matching retrospective cohort, January 2000 to December 2012                              Hospital Authority (HA) registry database, Hong Kong                                                                       Statin users: 1176\                                                                                          Statin users: 58.7±12.4\                 NR                                   HBV (all patients)                                             Statin users: 1.6 years (0.7--3.9)\    cDDD: 291.5                                                                 aHR               --
                                                                                                                                                                                                                                                                                            Non-users:\                                                                                                  Non-users: 58.9±12.9                                                                                                                         Non-users: 2.6 years (1--5.1)                                                                                                        
                                                                                                                                                                                                                                                                                            52337                                                                                                                                                                                                                                                                                                                                                                                          

  Kaplan, 2019 \[[@B17-cancers-12-00874]\]            Propensity score matching retrospective cohort, 1 January 2008 through 30 June 2016                        Veterans' Health Administration                                                                                            Statin users: 21921\                                                                                         Statin users: 64 (60--69)\               Statin users: 21373 (97.5%)\         Statin users: NR/2457 (11.2%)/8471 (38.6%)/5158 (23.5%)\       Statin users: 900 days (478--1546)\    270 days (0--827)                                                           aHR               Race, liver disease etiology, liver function tests, cirrhosis, comorbidities, BMI
                                                                                                                                                                                                                                                                                            Non-users: 51023                                                                                             Non-users: 63 (58--68)                   Non-users: 12602 (98%)               Non-users: NR/2065 (14.9%)/4876 (35.2%)/2159 (15.6%)           Non-users: 1970 days (1234--2736)                                                                                                    

  Kim, 2018 \[[@B18-cancers-12-00874]\]               Nested case--control study, 2002--2013                                                                     National Health Insurance Service Physical Health Examination in the Republicof Korea.                                     HCC group: 1642 patients of which 111 statin users Non-HCC group: 8210 patients of which 1047 statin users   HCC group: 61.8±9.2\                     HCC group: 1372 (83.6%)\             HCC group: 755 (46%)/NR/277 (16.9%)/NR\                        NR                                                                                                                 OR, aOR           Comorbidities, cirrhosis, BMI, other drugs, household income level
                                                                                                                                                                                                                                                                                                                                                                                                         Non-HCC group: 61.8±9.2                  Non-HCC group: 6860 (83.6%)          Non-HCC group: 232 (2.8%)/NR/418 (5.1%)/NR                                                                                                                                                          

  King, 2013 \[[@B19-cancers-12-00874]\]              Prospective cohort                                                                                         USA                                                                                                                        136178                                                                                                       NR                                       NR                                   NR                                                             \>20 years                                                                                                         aHR               Age, BMI, comorbidities, other drugs

  Lai, 2013 \[[@B20-cancers-12-00874]\]               Case--Control study, 2000--2009                                                                            Taiwan National Health Insurance program                                                                                   HCC group: 3480 patients of which 255 statin users Non-HCC: 13920 patients of which 1635 statin users        HCC group:\                              HCC group: 2525 (72.6%)\             HCC group:\                                                    9 years                                HCC group: 16.7 months\                                                     OR, aOR           Age, sex, comorbidities, cirrhosis, etiology of liver disease, other drugs
                                                                                                                                                                                                                                                                                                                                                                                                         62.7±13.4\                               Non-HCC: 10100 (72.6%)               1295 (37.2%)/1005 (28.9%)/66 (1.90%)/72 (2.07%)\                                                      Non-HCC: 18.6 months                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                         Non-HCC: 62.2±13.7                                                            Non-HCC: 424 (3.05%)/274 (1.97%)/75 (0.54%)/86 (0.62%)                                                                                                                                              

  McGlynn, 2014 \[[@B21-cancers-12-00874]\]           Nested case--control, between 1999 and 2010                                                                Population of the Health Alliance Plan HMO of the Henry FordHealth System (HFHS), a single integrated health system. USA   HCC group: 94 patients of which 25 statin users\                                                             Mean NR                                  HCC group: 70 (74.47%)\              HCC group: 1 (1.06%)/46 (48.94%)/24 (25.53%)/NR\               NR                                     *≤2 years:* HCC group: 13\                                                  OR, aOR           Race, etiology of liver disease, comorbidities
                                                                                                                                                                                                                                                                                            Non-HCC group: 468 patients of which 233 statin users                                                                                                 Non-HCC group: 348 (74.36%)          Non-HCC group: 1 (0.21%)/8 (1.71%)/4 (0.85%)/NR                                                       Control group: 105\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *\> 2 years use of statin:* HCC group: 12\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Control: 128                                                                                  

  McGlynn, 2015 \[[@B22-cancers-12-00874]\]           Nested case--control, 1988 and 2011                                                                        UK's Clinical Practice Research Datalink (CPRD).                                                                           HCC group: 1195 patients of which 302 statin users\                                                          HCC group: 97.2±12.1\                    HCC group: 856 (71.6%)\              HCC group: 74 (6.2%)/189 (15.8%)/170 (14.2%)\                  NR                                     *Cumulative dose: \<8120)*\                                                 OR, aOR           BMI, etiology of liver disease, comorbidities, other drugs used
                                                                                                                                                                                                                                                                                            Non-HCC group: 4640 patients of which 1242 statin users                                                      Non-HCC group: 67±12.1                   Non-HCC group: 3322 (71.6%)          Non-HCC group: 23/(0.5%)/189 (4%)/9 (0.2%)                                                            HCC: 168 (14.1%)\                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Control: 642 (13.2%)\                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *\>(21 281*\                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             HCC: 152 (12.7%)\                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Control: 649 (14%)                                                                            

  Mohanty, 2016 \[[@B23-cancers-12-00874]\]           Propensity score matching retrospective cohort, January 1996 through December 2009                         Veteran Affairs Clinical Case Registry, which contains nationwide data from veterans infected with the HCV                 Statin users: 685\                                                                                           Statin users: 56 (52--59)\               Statin users: 677 (98.8%)\           All had HCV and compensated cirrhosis                          NR                                     NR                                                                          HR                --
                                                                                                                                                                                                                                                                                            Non-users: 685                                                                                               Non-users: 56 (52--60)                   Non-users: 671 (97.9%)                                                                                                                                                                                                                   

  Simon, 2019 \[[@B24-cancers-12-00874]\]             Propensity score matching cohort study, 2005--2013                                                         Swedish registers                                                                                                          Statin users: 16668\                                                                                         Statin users: 47.3±11\                   Statin users: 65.2%\                 Statin users: 1540 (23.5%)/5014/6554 (76.5%)/NR\               8 years                                NR                                                                          aHR               Age, sex, duration of viral infection, cirrhosis, comorbidities, other drugs used
                                                                                                                                                                                                                                                                                            Non-users: 8334                                                                                              Non-users: 47.5±13.7                     Non-users: 65.6%                     Non-users: 1953 (23.4%)/6381/76.6%                                                                                                                                                                  

  Tran, 2019 \[[@B25-cancers-12-00874]\]              Nested case--control, 1999-2011                                                                            Scottish Primary Care Clinical Informatics Unit (PCCIU) database.                                                          HCC group: 434 patients of which 111 statin users\                                                           Mean NR                                  HCC group: 292 (67.3%)\              NR                                                             NR                                     HCC group: 4.88 years (3.1--7.29)\                                          OR, aOR           Age, sex, obesity, comorbidities, other drugs used, alcohol
                                                                                                                                                                                                                                                                                            Non-HCC group: 2103 patients of which 571 statin users                                                                                                Non-HCC group: 1412 (67.1%)                                                                                                                Non-HCC group: 4.83 years (3.1--7.24)                                                         

  Tran, 2019 (II) \[[@B25-cancers-12-00874]\]         Prospective cohort                                                                                         UK Biobank                                                                                                                 Statin users: 395301\                                                                                        Mean NR                                  NR                                   NR                                                             NR                                     NR                                                                          OR                Age, sex, body mass index, alcohol, comorbidities, other drugs used
                                                                                                                                                                                                                                                                                            Non-users: 76550                                                                                                                                                                                                                                                                                                                                                                               

  Tsan, 2012 \[[@B27-cancers-12-00874]\]              Retrospective cohort, 1997--2008                                                                           Taiwan National Health Insurance\                                                                                          Statin users: 2785\                                                                                          Statin users: 34.7 (26.6--43.8)\         Statin users: 1590 (57.1%)\          All patients have HBV                                          NR                                     28--90 cDDD: 933 (33.5%)\                                                   HR, aHR           Age, sex, income, diabetes, and liver cirrhosis
                                                                                                                                                                 Research Database                                                                                                          Non-users: 30628                                                                                             Non-users: 46.3 (38.9--55.3)             Non-users: 17852 (58.3%)                                                                                                                   91--356 cDDD: 1279 (45.9%)\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \>365 cDDDs: 573 (20.6%)                                                                      

  Tsan, 2013 \[[@B26-cancers-12-00874]\]              Retrospective cohort, 1 January 1999 to 31 December 2010                                                   Taiwan National Health Insurance Research Database                                                                         Statin users: 35023\                                                                                         Statin users: 53.9 (45.4--62.1)\         Statin users: 14973 (42.8%)\         All patients had HCV                                           Statin users: 12 years (12.0--12.0)\   179.6 CDD (80.0--414.7)                                                     HR, aHR           Age, sex, urbanization, income, liver cirrhosis, and diabetes
                                                                                                                                                                                                                                                                                            Non-users: 225841                                                                                            Non-users: 49.8 (38.9--62)               Non-users: 113290 (50.2%)                                                                           Non-users: 12 years (10.9--12)                                                                                                       

  Sato, 2006 \[[@B28-cancers-12-00874]\]              RCT\                                                                                                       Japan                                                                                                                      Statin users: 179\                                                                                           NR                                       NR                                   NR                                                             NR                                     All patients used pravastatin                                               OR, aOR           --
                                                      28 September 1991 and 31 March 1995                                                                                                                                                                                                   Non-users: 84                                                                                                                                                                                                                                                                                                                                                                                  

  Marelli, 2011 \[[@B29-cancers-12-00874]\]           Retrospective cohort, propensity score matching, 1990--2009                                                General Electric Centricity electronic medical records database                                                            Statin users: 45857\                                                                                         Statin users: 64.2±10.44\                Statin users: 23953 (52.23%)\        Viral\                                                         Statin users: 8.43 years\              NR                                                                          OR, aOR           --
                                                                                                                                                                                                                                                                                            Non-users: 45857                                                                                             Non-users: 64.19±9.45                    Non-users: 24106 (52.57%)            28 (0.06%)\                                                    Non-users: 8.43 years                                                                                                                

  Friis, 2005 \[[@B30-cancers-12-00874]\]             Population-based cohort study, 1989--2002                                                                  The Prescription Database of North Jutland County and the Danish Cancer Registry                                           Statin users: 12251\                                                                                         Statin users: 60.7\                      6935 (57%)\                          NR                                                             3.3 years (0--14)                      Number of statin prescriptions:\                                            aOR               Age, gender, other drugs used
                                                                                                                                                                                                                                                                                            Non-users: 322503                                                                                            Non-users: 53.9                          707 (56%)                                                                                                                                  2--4: 2392 (20%)\                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             5--9: 2516 (21%)\                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             10--19: 3282 (27%)\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             20+: 4061 (33%)                                                                               

  Matsushita, 2010 \[[@B31-cancers-12-00874]\]        Individual patient meta-analysis of RCT                                                                    Multicenter                                                                                                                Statin users: 7375\                                                                                          Statin users: 57.9±8.3\                  Statin users: 47.4%\                 NR                                                             5.3 years                              All patients used pravastatin                                               OR, aOR           --
                                                                                                                                                                                                                                                                                            Non-users: 6349                                                                                              Non-users: 57.1±8.7                      Non-users: 49.5%                                                                                                                                                                                                                         

  Emberson, 2012 \[[@B32-cancers-12-00874]\]          Individual patient meta-analysis from RCTs                                                                 International                                                                                                              Statin users: 67258\                                                                                         63                                       46675 (27%)                          NR                                                             4.9 years                              NR                                                                          OR, aOR           --
                                                                                                                                                                                                                                                                                            Non-users: 67279                                                                                                                                                                                                                                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are reported as mean (standard deviation or interquartile range) or absolute number (percentage). Abbreviations: aHR, Adjusted hazard ratio; aOR, Adjusted odds ratio; cDDD, Cumulative defined daily dose; HCC, Hepatocellular carcinoma; HCV: Hepatitis C virus; HR, Hazard ratio; OR, Odds ratio; NR, Not reported; RCT, Randomized controlled trial.

cancers-12-00874-t002_Table 2

###### 

Subgroup analysis for adjusted hazard ratio concerning hepatocellular carcinoma occurrence.

  Variable                        Subgroup     Studies (*n*)        Summary Estimate (95% CI)   Within-Group Heterogeneity (I^2^)
  ------------------------------- ------------ -------------------- --------------------------- -----------------------------------
  Etiology of liver disease       HBV          2                    0.46 (0.36--0.60)           0%
  HCV                             2            0.68 (0.30--1.55)    66%                         
  Diabetes                        Yes          5                    0.52 (0.46--0.58)           0%
  No                              4            0.43 (0.31--0.61)    58%                         
  Cumulative defined daily dose   ≤365         3                    0.51 (0.30--0.88)           78%
  \>365                           3            0.27 (0.11--0.67)    81%                         
  Molecule                        Lipophilic   2                    0.49 (0.39--0.62)           19%
  Hydrophilic                     2            0.73 (0.40--1.34)    83%                         
  Simvastatin                     2            0.69 (0.42--1.15)    55%                         
  Atorvastatin                    2            0.43 (0.28--0.65)    17%                         
  Fluvastatin                     2            1.02 (0.08--13.25)   83%                         
  Pravastatin                     1            0.80 (0.46--1.39)    NA                          
  Rosuvastatin                    2            0.53 (0.04--6.38)    86%                         

Abbreviation: CI, Confidence interval; HBV, Hepatitis B virus; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus.

cancers-12-00874-t003_Table 3

###### 

Sensitivity analysis of the main diagnostic outcome (odds ratio for hepatocellular carcinoma occurrence) performed based on: (a) study design (observational versus RCT); (b) study location (Asia versus western); and (c) study quality (high versus low).

  Variable                                                                   Subgroup        Studies (*n*)       Summary Estimate (95% CI)   Within-Group Heterogeneity (I^2^)
  -------------------------------------------------------------------------- --------------- ------------------- --------------------------- -----------------------------------
  Study design                                                               Observational   16                  0.52 (0.41--0.73)           87%
  RCT                                                                        3               0.98 (0.76--1.32)   45%                         
  Study location                                                             Asia            8                   0.51 (0.43--0.65)           44%
  Western                                                                    8               0.59 (0.45--0.81)   34%                         
  Study quality                                                              High            13                  0.54 (0.44--0.89)           39.4%
  Low                                                                        3               0.57 (0.41--0.98)   55%                         
  Abbreviations: CI, Confidence Interval; RCT, Randomized-Controlled Trial                                                                   
